Novel Interventions to Prevent HIV and HCV Among Persons Who Inject Drugs

被引:0
作者
Phillip O. Coffin
Christopher Rowe
Glenn-Milo Santos
机构
[1] San Francisco Department of Public Health,
[2] University of California San Francisco,undefined
[3] University of California Berkeley,undefined
来源
Current HIV/AIDS Reports | 2015年 / 12卷
关键词
Injection drug use (IDU); HIV; Hepatitis C; Behavioral interventions; Pharmacotherapies; Overdose;
D O I
暂无
中图分类号
学科分类号
摘要
Persons who inject drugs (PWID) are at high risk for infection with and poor outcomes from HIV and hepatitis C virus (HCV). Well-established interventions for HIV/HCV prevention among PWID include syringe access, opioid agonist maintenance treatment, and supervised injection facilities, yet these interventions remain unavailable or inadequately resourced in much of the world. We review recent literature on biomedical and behavioral interventions to reduce the burden of HIV/HCV among PWID, with an emphasis on randomized controlled trials and quasi-experimental studies. Since 2013, there have been significant advancements in utilizing antiviral therapy and behavioral interventions for prevention among PWID, including approaches that address the unique needs of couples and sex workers. In addition, there have been significant developments in pharmacotherapies for substance use and the implementation of naloxone for opioid overdose prevention. Notwithstanding multiple ongoing structural challenges in delivering HIV/HCV prevention interventions to PWID, these emerging and rigorously evaluated interventions expand possibilities for prevention among PWID.
引用
收藏
页码:145 / 163
页数:18
相关论文
共 467 条
[1]  
Mathers BM(2008)Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review Lancet 372 1733-45
[2]  
Degenhardt L(2006)Risk of HIV-1 transmission for parenteral exposure and blood transfusion: a systematic review and meta-analysis AIDS 20 805-12
[3]  
Phillips B(2013)Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010 Lancet 382 1564-74
[4]  
Wiessing L(2014)Estimating the number of persons who inject drugs in the United States by meta-analysis to calculate national rates of HIV and Hepatitis C virus infections PLoS One 9 e97596-28
[5]  
Hickman M(2013)Virus and HIV type 1 co-infection Infect Dis Rep 5 e7-92
[6]  
Strathdee SA(2010)HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage Lancet 375 1014-301
[7]  
Baggaley RF(2013)Effectiveness of structural-level needle/syringe programs to reduce HCV and HIV infection among people who inject drugs: a systematic review AIDS Behav 17 2878-66
[8]  
Boily MC(2010)Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed Lancet 376 285-505
[9]  
White RG(2010)Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward Lancet 376 355-5
[10]  
Alary M(2011)Prevention of HIV-1 infection with early antiretroviral therapy N Engl J Med 365 493-90